Prediction of midazolam - CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data

Drug Metabolism and Disposition

Volumn 29, Issue 4 I, 2001, Pages 443-452

  Yamano, Katsuhiro ^a,b   Yamamoto, Koujirou ^c   Katashima, Masataka ^a,b   Kotaki, Hajime ^d   Takedomi, Sayuri ^e   Matsuo, Hirotami ^e   Ohtani, Hisakazu ^e   Sawada, Yasufumi ^e   Iga, Tatsuji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYTOCHROME P450 3A; ERYTHROMYCIN; ITRACONAZOLE; MIDAZOLAM;

AEROBIC METABOLISM; ARTICLE; BINDING AFFINITY; DATA ANALYSIS; DRUG ABSORPTION; DRUG DISPOSITION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN TISSUE; LIVER METABOLISM; PREDICTION; PRIORITY JOURNAL;

ANESTHETICS, INTRAVENOUS; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CIMETIDINE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; ERYTHROMYCIN; HUMANS; INTESTINAL ABSORPTION; ITRACONAZOLE; KINETICS; LIVER; MALE; MICROSOMES, LIVER; MIDAZOLAM; MODELS, BIOLOGICAL; OXIDOREDUCTASES, N-DEMETHYLATING; PORTAL VEIN; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0035064595     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers
2. Distribution of cimetidine in postmortem tissues
3. Cytochrome P450 turnover
4. Physiological parameters in laboratory animals and humans
5. Dual effects of macrolide antibiotics on rat liver cytochrome P-450 induction and formation of metabolite-complexes: A structure activity relationship
6. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice
7. Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds
8. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam
9. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
10. Bioavailability and pharmacokinetics of cimetidine
11. Molecular and physical mechanisms of first-pass extraction
12. Pharmacokinetics of intraconazole following oral administration to normal volunteers
13. The pharmacokinetics of itraconazole in animals and man: An overview
14. Method to estimate the rote and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling
15. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
16. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
17. Determination of cimetidine in human plasma by high-performance liquid chromatography following liquid-liquid extraction
18. Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam
19. Pharmacokinetics of single-dose crythromycin in normal and alcoholic liver disease subjects
20. Selective inhibition of rat hepatic cytochrome P-450. I. Effect of the in vitro administration of cimetidine
21. Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base
22. The CYP3A family
23. Phase 1 study on itraconazole (ITZ), an oral triazole antifungal; Safety of ITZ in healthy subjects after single and multiple oral administrations
24. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
25. A potentially hazardous interaction between erythromycin and midazolam
26. In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin
27. Absorption of erythromycin stearate and enteric-coated erythromycin based after a single oral dose immediately before breakfast
28. Interindividual variations in human liver cytochrome P-450 enzyme involved in the oxidation of drugs carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
29. Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats
30. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
31. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents
32. Bioavailability of cimetidine in man
33. Relationship between hepatic cytochrome P4503A content and activity and the disposition of midazolam administered orally
34. Human cytochrome P450 3A4-catalyzed testerone 6β-hydroxylation and erythromycin N-demethylation
35. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine
36. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: Implication of concentrative uptake of inhibitors into liver
37. Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: Implication of concentrative uptake of inhibitors into liver
38. A pharmacokinetics analysis program (MULTI) for microcomputer
39. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics
40. The partitioning of cimetidine, into canine cerebrospinal fluid